Multiple Myeloma Research Consortium
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Employees
- -
- Market Cap
- -
MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Multiple Myeloma Research Consortium
- Target Recruit Count
- 300
- Registration Number
- NCT06171685
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT
- First Posted Date
- 2019-11-05
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Multiple Myeloma Research Consortium
- Target Recruit Count
- 14
- Registration Number
- NCT04150965
- Locations
- 🇺🇸
Hackensack Meridian Medical Center, Hackensack, New Jersey, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Emory University, Atlanta, Georgia, United States
Myeloma-Developing Regimens Using Genomics (MyDRUG)
Phase 1
- Conditions
- Interventions
- Drug: Abemaciclib, dexamethasone, ixazomib, pomalidomideDrug: Enasidenib, dexamethasone, ixazomib, pomalidomideDrug: Cobimetinib, dexamethasone, ixazomib, pomalidomideDrug: Erdafitinib, dexamethasone, ixazomib, pomalidomideDrug: Venetoclax, dexamethasone, ixazomib, pomalidomideDrug: Daratumumab, dexamethasone, ixazomib, pomalidomideDrug: Belantamab mafodotin, dexamethasone, ixazomib, pomalidomideDrug: Selinexor, dexamethasone, ixazomib, pomalidomide
- First Posted Date
- 2018-11-07
- Last Posted Date
- 2021-09-10
- Lead Sponsor
- Multiple Myeloma Research Consortium
- Target Recruit Count
- 228
- Registration Number
- NCT03732703
- Locations
- 🇺🇸
Ohio State University College of Medicine, Columbus, Ohio, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸Emory University, Atlanta, Georgia, United States
© Copyright 2024. All Rights Reserved by MedPath